Brief: Theradiag receives CE marking for its Herceptin monitoring
11/03/2015 17:00
March 11 (Reuters) - Theradiag SA ALTHE.PA :
* Theradiag strengthens its positioning in the oncology
theranostics market with its herceptin monitoring test receiving
CE marking
* Herceptin/Trastuzumab is a humanized monoclonal antibody
designed to block tumor growth by interfering with HER2 receptor
Source text for Eikon: ID:nBw7Z02pca
Further company coverage: ALTHE.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))